Etats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020 https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/ GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]
Lire la suiteEffect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults Anthony N. Nicholson, MD, PhD, Claire Turner, BSc, Barbara M. Stone, PhD, and Philip J. Robson, MDy Journal of Clinical Psychopharmacology, 2004, Volume 24, Number 3, 305-313. Doi : 10.1097/01.jcp.0000125688.05091.8f Abstract : The effects of cannabis extracts on nocturnal sleep, earlymorning performance, memory, and sleepiness were studied in 8 healthy volunteers (4 males, 4 females; 21 to 34 years). The study was double-blind and placebo-controlled with a 4-way crossover design. The 4 treatments were placebo, 15 mg D-9-tetrahydro-cannabinol (THC), 5 mg THC combined with 5 mg cannabidiol (CBD), and 15 mg [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteCannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting Toni Leigh Mortimer, Tom Mabin & Anna-Mart Engelbrecht Future Oncology, 2019 Doi : 10.2217/fon-2018-0530 Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and -9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Although there are many preclinical and clinical studies on the effects of -9- tetrahydrocannabinol during nausea and vomiting, little is known about the role [...]
Lire la suiteShort- and Long-Term Effects of Cannabis on Headache and Migraine Carrie Cuttler, Alexander Spradlin, Michael J. Cleveland, and Rebecca M. Craft Journal of Pain, 2019. doi : 10.1016/j.jpain.2019.11.001 Highlights Headache and migraine ratings were reduced by nearly 50% after using cannabis Men reported larger reductions in headache after cannabis use than women Cannabis concentrates were related to larger reductions in headache than flower Evidence for tolerance to effects of cannabis on headache and migraine was detected Evidence for medication overuse headache was not detected Abstract Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to [...]
Lire la suiteCannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226 BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]
Lire la suiteCannabis is Not a Suitable Human Coronavirus Treatment Marc Moulin March 20, 2020 https://www.rxleaf.com/cannabis-not-good-human-coronavirus-treatment/ Using cannabis as a human coronavirus treatment may make symptoms worse. Cannabis is great for a lot of things. For example, many physical conditions see symptom abatement with cannabinoid treatment. Additionally, there is adequate, and in some cases, strong, scientific evidence to support consuming cannabis for therapeutic relief. Unfortunately, fighting off influenza-like viruses is not one of them. It’s important to note that there is absolutely no evidence to suggest that cannabis is an effective human coronavirus treatment. On the contrary, researchers from Michigan State University provide recent evidence to demonstrate potentially harmful [...]
Lire la suiteCannabis and Coronavirus : What Cannabis Patients Want to Know Jennifer Grant https://www.rxleaf.com/cannabis-and-coronavirus-what-cannabis-patients-want-to-know/ February 17, 2020 There is evidence that cannabis can reduce viral load in HIV, can it help COVID-19 patients? At the time of writing, there were 69, 287 confirmed cases of the coronavirus and 1670 deaths. With the rapid escalation of the outbreak, these numbers will surely be outdated by the time of publication. With several regions heading into states of emergencies, including quarantine, nervous travelers are looking for anti viral herbs to reduce the chance of infection. Patients have asked us: What about cannabis? There have been rumors about successful treatments for coronavirus, [...]
Lire la suiteAbuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027 a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]
Lire la suiteAutorisation Temporaire Exceptionnelle d'Utilisation compassionelle du cannabis médical Laurent Appel (conseil en communication spécialisé en réduction des risques) 06.81.54.10.96 mailto : laurent.appel@asud.org relayé par www.Principesactifs.org, 26/03/2020 La chaine de soins et de médicament est en tension maximum. Le rôle de chacun est de détecter les failles actuelles et surtout futures pour éviter d'ajouter encore de la tension et faire tout sauter.Le cannabis médical peut jouer un rôle majeur tant comme solution thérapeutique alors que qon manque sera un facteur important de tensions. D'un point de vue médical, il va manquer aux patients déjà traités clandestinement et surtout au million de patients en automédication. Nous risquons donc avoir [...]
Lire la suite